You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Fluorescence lifetime imaging device for 5-ALA-guided neurosurgery

    SBC: HILIGHT SURGICAL, INC.            Topic: 394

    PROJECT SUMMARY 5-ALA-induced PpIX fluorescence-guided surgery (FGS) enables real-time visualization of residual cancer tissue during resection of brain tumors. This addresses a critical need in surgical oncology as the ability to identify residual tumor leads to improvements in overall survival, whereas the sparing of normal tissue benefits the patient’s quality of life. Currently, surgeons vis ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Identification of Mixed NOP/mu partial agonists as lead compounds for treatment ofmethamphetamine use disorder

    SBC: PHOENIX PHARMALABS, INC.            Topic: NIDA

    Abstract Currently, clinically used drug abuse medications exist for treatment of addiction to opiates, alcohol, and nicotine, but not psychostimulants, such as methamphetamine (METH). Compounds that co-activate both nociceptin opioid peptide (NOP) and mu receptors have potential for treatment of drug abuse. In particular, buprenorphine, a partial mu agonist/kappa antagonist, which also acts as a ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Feasibility and design of a novel smartphone app to deliver blood pressure-lowering inspiratory muscle strength training

    SBC: KLEIN BUENDEL, INC.            Topic: NHLBI

    PROJECT SUMMARYHigh blood pressure (BP), particularly high systolic BP (SBP), is the major modifiable risk factor for cardiovascular diseases (CVD) and related conditions. Indeed, over 50% of all adults have above-normal SBP (≥120 mmHg), placing them at increased disease risk. In addition, these adults face ~$2000/year in excess medical expenses compared to their peers with normal BP. Rates of B ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Targeting glioblastoma with CM93, a novel EGFR inhibitor with exceptional brain penetration

    SBC: CRIMSON BIOPHARM INC            Topic: NCI

    PROJECT SUMMARY The epidermal growth factor receptor (EGFR) gene is mutated and/or amplified in majority of primary glioblastoma (GBM). While EGFR-mutant GBM cancer cells are dependent on EGFR signaling for survival, numerous small molecule EGFR tyrosine kinase inhibitors (TKIs) have failed to show efficacy in this disease. There are two main reasons for these failures: i) Many of these EGFR-TKIs ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a ZIKA viral pseudoinfectious virus as ZIKA vaccine candidate (STTR Phase II)

    SBC: Tengen Biomedical Co            Topic: NIAID

    Development of Zika viral pseudoinfectious virus as zika vaccine candidate(Phase 2) Abstract Zika virus epidemics and the association of ZIKV infection with Guillain–Barré syndrome, and congenital disabilities, including microcephaly, led the World Health Organization to declare ZIKV a “Public Health Emergency of International Concern” in 2016. Since then, various ZIKV vaccine platforms hav ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  6. New Agents for the Treatment on Mycobacteria Avium Infections

    SBC: Quercus Molecular Design, LLC            Topic: NIAID

    Abstract: Non-Tuberculosis Mycobacteria (NTM) are responsible for widespread, life threatening infections of the lungs, skin, lymphatic and hematological systems. The rapid, global spread of resistant organisms has significantly reduced the number of agents that can be used effectively to treat these infections. Of specific clinical relevance are the slow-growing Mycobacterium avium complex (MAC) ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  7. Novel Treatment for Alcohol-associated Liver Disease

    SBC: MITOTHERAPEUTIX, LLC            Topic: 350

    Abstract The Specific Aim of this Phase I TTR proposal is to test the feasibility of our siRNA drug to ameliorate the pathology and progression of alcohol-associated liver disease (ALD). Alcohol consumption remains a leading cause of hepatic pathology worldwide and is one of the greatest sources of preventable morbidity and mortality. In the U.S., alcohol abuse impacts over 10 million individuals ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a Bio-tissue Oxygenation Nanophosphor Enabled Sensing (BONES) system for Quantifying Hypoxia in Bone Marrow

    SBC: SIGRAY, INC.            Topic: 400

    Project Summary/Abstract Low oxygen (hypoxic) environments are known to be important for maintaining the small number of adult stem cells in the human body, such as in bone marrow. These conditions are also believed to enable dormant cancer cells to survive and metastasize years or decades after the original tumor has been destroyed and the reason why bone marrow is one of the most common sites of ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  9. Biomarker-enhanced Artificial Intelligence-Based Pediatric Sepsis Screening Tool Towards Early Recognition and Personalized Therapeutics

    SBC: COMPUTER TECHNOLOGY ASSOCIATES, INC.            Topic: NIAID

    PROJECT SUMMARY The overall objective of this proposed STTR effort is focused on the derivation and validation of a commercialized biomarker-enhanced artificial intelligence (AI)-based pediatric sepsis screening tool (PSCT) that can be incorporated into emergency department (ED) workflows to enhance early recognition and the initiation of timely, aggressive personalized sepsis therapy. The early r ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  10. Feasibility of a mobile application for sleep and circadian rhythms in pediatric patients with acute lymphoblastic leukemia and their caregivers

    SBC: ARCASCOPE INC.            Topic: NHLBI

    ABSTRACT Long-term survival rates for children diagnosed with acute lymphoblastic leukemia (ALL) currently exceed 90%. However, prolonged ALL chemotherapy, which lasts two to three years on average, is associated with significant fatigue and sleep disturbances in both children and their caregivers. In fact, patients and caregivers often identify excess fatigue and sleep disturbances as the most di ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government